Acucela Inc. to Present ACU-4429 Phase 1 Data at the 10th International Symposium on Ocular Pharmacology and Therapeutics
11/30/2011 9:11:30 AM
SEATTLE & VIENNA--(BUSINESS WIRE)--Acucela Inc., a Washington State-based clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced that data for ACU-4429, the Company’s novel, small-molecule visual cycle modulator (VCM) for the treatment of dry age-related macular degeneration (dry AMD), will be highlighted at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Vienna, Austria from December 1-4, 2011. John W. Chandler, M.D., Acucela’s vice president clinical affairs, will present: “Progress in the Development of ACU-4429 for the Treatment of Dry AMD” during the Retina: Dry AMD portion of the ISOPT program on December 1, 2011, at 4:40 p.m. local time.
comments powered by